The impact of this deal on the stock market has been quite bullish, especially for AI-related companies and those involved in ...

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of uncertainties ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its first death from the virus.

The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...

President Donald Trump talked up a joint venture investing up to $500 billion for infrastructure tied to AI by a new ...